Research Analysts Issue Forecasts for MetaVia Q4 Earnings

MetaVia Inc. (NASDAQ:MTVA) – Research analysts at HC Wainwright lifted their Q4 2025 earnings per share (EPS) estimates for MetaVia in a report released on Tuesday, January 6th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($1.82) per share for the quarter, up from their previous estimate of ($1.87). HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.90) per share. HC Wainwright also issued estimates for MetaVia’s Q1 2026 earnings at ($2.01) EPS, Q2 2026 earnings at ($2.22) EPS, Q3 2026 earnings at ($2.45) EPS, Q4 2026 earnings at ($3.06) EPS and FY2026 earnings at ($12.30) EPS.

MTVA has been the topic of several other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research note on Monday, December 22nd. Wall Street Zen raised MetaVia to a “sell” rating in a research report on Saturday, January 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $36.50.

MetaVia Trading Down 2.7%

NASDAQ:MTVA opened at $8.15 on Friday. The firm has a fifty day simple moving average of $8.70 and a 200 day simple moving average of $8.73. MetaVia has a 1-year low of $6.05 and a 1-year high of $24.03. The stock has a market capitalization of $17.93 million, a PE ratio of -0.97 and a beta of 0.27.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($1.54) earnings per share for the quarter, topping the consensus estimate of ($2.86) by $1.32.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned approximately 0.14% of MetaVia as of its most recent filing with the SEC. 1.37% of the stock is owned by institutional investors.

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.